Better Health for All

MindMed's core business is developing treatments for brain health disorders, including anxiety, depression, autism spectrum disorder, ADHD, and opioid withdrawal.

However, the therapies are still under investigation, and their safety and efficacy have not yet been established or approved by health authorities. Therefore, the net health effect of its principal goods or services is currently neutral from a proven benefit perspective. The company's product candidates are controlled substances, which may generate public controversy and require compliance with strict regulations, including potential requirements for additional data on abuse potential. The company explicitly states that its therapies are not FDA-approved and are still being evaluated. MindMed acknowledges that successful commercialization depends on adequate reimbursement and pricing policies, and that government cost containment efforts could impact pricing. The company's digital medicine programs aim to diagnose, prevent, manage, or treat brain health disorders, and it is developing a Session Monitoring System (MSMS) to help healthcare professionals monitor patients during consciousness-altering sessions. MindMed participates in the Digital Medicine Society's DATAcc, which aims to ensure equitable access to digital health technologies. The company's R&D programs include non-clinical, pre-clinical, and human clinical trials, as well as partnerships for next-generation compounds and digital medicine programs. MindMed adheres to ethical standards for clinical trials, including GCPs, IRB review, informed consent, and adverse event reporting, but there is no evidence of exceptional or industry-leading practices. The company's MM-110 is being developed for opioid withdrawal, with preclinical studies showing it reduces signs of withdrawal and self-administration of various substances.

Fair Pay & Worker Respect

Mind Medicine (now Definium Therapeutics) reports that none of its employees are members of a union or covered by collective bargaining agreements.

The company states that its relationships with employees are good. The company has an employee rating of 92 out of 100, which outperforms all listed industry peers including Johnson & Johnson, Eli Lilly, Pfizer, AstraZeneca, and AbbVie. As of December 31, 2024, the company had 74 full-time employees. The voluntary employee turnover rate cannot be meaningfully assessed due to the small workforce headcount.

Honest & Fair Business

MindMed has a formal whistleblower protection policy that includes an anonymous hotline, but there is no evidence regarding independent investigation processes.

The company's board consists of 6 directors, with 4 identified as non-independent, meaning approximately 33% are conflict-free. MindMed has an anti-corruption and anti-bribery policy that explicitly addresses FCPA compliance, covers foreign and domestic officials, private sector actors, and includes detailed procedures for transactions, travel, gifts, political contributions, and plans for training, due diligence, and audits. However, the policy lacks customization for high-risk areas. Audits of sites, operating units, and contractors may be conducted internally or externally by third parties, but no specific details on the extent of independent verification are provided, indicating less than 10% of ethical claims are independently verified.

Kind to Animals

MindMed conducts preclinical studies using animal models, specifically mentioning 'Fmr1 knockout mice' for autism spectrum disorder research.

The company's R&D expenses were $52.1 million for the year ended December 31, 2023, and $36.2 million for the year ended December 31, 2022. However, the provided articles do not contain specific data points or percentages required to score any of the KPIs related to cruelty-free certifications, alternative testing usage, humane certifications, wildlife conservation, ethical input substitution, supplier audits, cage-free sourcing, animal testing policy details, animal testing volume, investment in animal-free technologies, animal agriculture ethics, animal-free R&D collaboration, or public policy engagement on animal welfare.

Planet-Friendly Business

The provided articles do not contain specific, quantitative data points for Mind Medicine (MindMed) Inc. (MNMD.US) across any of the Planet-Friendly Business KPIs.

Multiple sources explicitly state a lack of detailed ESG metrics, sustainability targets, and supply chain practices for the company. Information presented in one article pertains to a different company, Mindera, and is therefore not applicable to MNMD.US. Consequently, no KPIs can be scored based on the available evidence.

Safe & Smart Tech

Mind Medicine (MindMed) Inc. has not experienced any cybersecurity threats that materially affected its business strategy, operations, or financial condition in the last year, as of December 31, 2024.

The company states it will inform users of security breaches likely to have negative effects on privacy as soon as reasonably possible. The company processes Personal Identifiable Information (PII) in accordance with applicable laws and regulations and is subject to HIPAA, GDPR, and CCPA. It also states it is ready to protect PII and give options to exercise rights under CCPA once it becomes applicable.

Zero Waste & Sustainable Products

No information regarding Mind Medicine (MindMed) Inc.'s waste management practices, product sustainability, or related initiatives was found in the provided articles. The company's 10-K filing () explicitly states it does not contain information related to environmental sustainability, waste management, or product lifecycle.

Other articles discuss general healthcare industry practices or the efforts of other specific companies, which cannot be attributed to MNMD.US.